drugset / Trial / NCT04001647

Targeting ER Stress in Vascular Dysfunction

NCT04001647

Phase 0 Terminated 17 enrolled Colorado State University
RandomizedParallel-groupDouble-blindBasic science

Summary

Aging and obesity are both risk factors for cardiovascular disease (CVD). One process that links both of these conditions to CVD is vascular dysfunction. Data from animal studies indicate that endoplasmic reticulum (ER) stress may play an important role in the development of endothelial dysfunction in aging and obesity. Therefore, the goal of this study is to investigate the relative contributions of aging and obesity on vascular dysfunction and ER stress. Additionally, this study will determine if taking an oral supplement for 8 weeks will improve vascular dysfunction and ER stress. Results from this study have the potential to identify a safe treatment option for improving vascular function in aging and obese populations.

Timeline

Start
2019-06-01
Primary completion
2022-08-16
Completion
2022-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcholine Small molecule 1 ug Other
Subject Acetylcholine Small molecule 4 ug Other
Subject Acetylcholine Small molecule 8 ug Other
Subject Acetylcholine Small molecule 16 ug Other
Subject Sodium Nitroprusside Unknown 0.25 ug Other
Subject Sodium Nitroprusside Unknown 0.5 ug Other
Subject Sodium Nitroprusside Unknown 1 ug Other
Subject Sodium Nitroprusside Unknown 2 ug Other
Subject Taurursodiol Small molecule 1750 mg Oral
Subject Vitamin C Other / unclassified 0.02 g/kg Intravenous